# India Drug Repurposing Market

> India Drug Repurposing Market Research Report: Size, Share, Trend Analysis By Typess (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 15.0%
- **2024:** $ 25 Million
- **2025:** $ 28.75 Million
- **2035:** $ 116.33 Million
- **Key Players:** Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US)

**Report ID:** MRFR/Pharma/50636-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-drug-repurposing-market-52394

---

## Market Summary

## **India Drug Repurposing Market Overview**

As per MRFR analysis, the India Drug Repurposing Market Size was estimated at 12 (USD Million) in 2023. The India Drug Repurposing Market Industry is expected to grow from 13.52(USD Million) in 2024 to 61.72 (USD Million) by 2035. The India Drug Repurposing Market CAGR (growth rate) is expected to be around 14.802% during the forecast period (2025 - 2035)

**Key India Drug Repurposing Market Trends Highlighted**

The India Drug Repurposing Market is experiencing significant growth driven by several key market drivers. Increasing investment in research and development by both public and private sectors in India is a primary driver, encouraging exploration of existing drugs for new therapeutic uses. The Indian government has emphasized the importance of innovation in healthcare, providing support for initiatives that aim to shorten the drug development cycle and lower costs. Additionally, the rise in chronic diseases and the burden of infectious diseases have led to a heightened focus on cost-effective treatment options, further propelling interest in drug repurposing. 

Opportunities within the market include collaborations between pharmaceutical companies and academic institutions. Such partnerships can facilitate knowledge sharing and access to clinical data, propelling faster identification of candidates for repurposing. Moreover, with India being a hub for clinical trials, leveraging this capacity for repurposing studies is an area that can be further explored to enhance the drug development pipeline. Recent trends in the India Drug Repurposing Market show a shift towards prioritizing therapies that quickly meet pressing health challenges. 

As seen during the COVID-19 pandemic, the urgency for rapid deployment of therapies has highlighted the potential of repurposing existing drugs to address immediate public health crises.Furthermore, growing awareness and acceptance of personalized medicine in India are encouraging researchers to investigate tailored repurposing strategies, opening new pathways for treatment. Overall, the landscape is becoming dynamic as stakeholders aim to maximize the value of existing medications while addressing the evolving health needs of the population.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Drug Repurposing Market Drivers**

**Growing Prevalence of Chronic Diseases**

One of the main factors propelling the India Drug Repurposing Market Industry is the rising incidence of chronic illnesses like diabetes, cancer, and cardiovascular conditions in the country. The Indian Council of Medical Research (ICMR) projects that by 2030, there will be over 1.57 million cancer cases in India, up from over 1.16 million in 2018. This startling increase calls for creative approaches to medication research, which makes drug repurposing an economical and expedient strategy. 

Research projects to investigate repurposing current medications for more efficient cancer therapy are being aggressively pursued by reputable institutions such as the Tata Memorial Centre. In addition to supporting programs that support national healthcare goals, this scenario highlights the critical need for repurposed medications to treat the rising burden of chronic illnesses in India.

**Government Support for Pharmaceutical Research**

The Indian government has recognized the importance of pharmaceutical innovation, exemplified by policy supports like the National Biotechnology Development Strategy. This initiative aims to enhance research and development in the biotechnology sector, which includes drug repurposing. 

With a significant budget allocation directed towards public health and pharmaceuticals, the government's support is empowering organizations such as the Indian Pharmaceutical Alliance to foster research collaboration.These measures are expected to accelerate the pace of drug repurposing projects in India, thereby positively impacting the India Drug Repurposing Market Industry.

**Advent of Advanced Technologies**

The application of advanced technologies such as artificial intelligence and machine learning in drug discovery is transforming the drug repurposing landscape in India. With the increasing adoption of technology, companies like BioCon and Dr. Reddy's Laboratories are leveraging data analytics to identify new uses for existing drugs more efficiently. 

According to the Department of Science and Technology of the Government of India, the implementation of these technologies can potentially reduce the cycle time for drug discovery by up to 30%, making drug repurposing a more viable option for pharmaceutical companies.This technological advancement serves as a critical driver for the growth of the India Drug Repurposing Market Industry.

**India Drug Repurposing Market Segment Insights**

**Drug Repurposing Market Types Insights**

The India Drug Repurposing Market encompasses various Types that play a crucial role in addressing unmet medical needs and optimizing the existing drug portfolio. As the market grows, the Types such as Disease-centric, Target-centric, and Drug-centric strategies stand out for their unique approaches to improving healthcare outcomes in the country. Disease-centric strategies focus on repositioning existing drugs to tackle various diseases, significantly boosting treatment options for conditions that currently lack effective therapies.

This approach is particularly important in a diverse healthcare landscape like India, where diseases range from infectious to chronic, thus expanding the scope of available treatments for the vast population.

On the other hand, Target-centric strategies emphasize the molecular targets of drugs, allowing for a more personalized treatment approach. By identifying and utilizing existing medications that can impact specific biological pathways, this method can lead to better patient outcomes, especially in complex diseases like cancer and neurological disorders. This is vital for India, where the burden of chronic diseases is on the rise.

Furthermore, the Drug-centric segment focuses on understanding the properties of established drugs that can be applied to new therapeutic areas, meaning that the existing drug candidates can be rapidly adapted for new uses, which is crucial in a country aiming for sustainable healthcare solutions.

These Types of the India Drug Repurposing Market not only facilitate quicker access to treatments but also reduce the financial burden of Research and Development (R&D). The market's growth is driven by advanced computational methods, better understanding of disease mechanisms, and an urgent need for innovative therapies in an ever-expanding patient population. The popularity of Drug Repurposing is magnified by the considerable cost and time it saves compared to developing new drugs from scratch, making it a significant focus area for both public and private stakeholders in India's healthcare ecosystem. 

As the industry continues to evolve, the segmentation of the India Drug Repurposing Market into these Types is essential in guiding research priorities, resource allocation, and ultimately ensuring that treatment landscapes are significantly improved for the growing number of patients with diverse health challenges in the country. Emphasizing this approach may provide substantial opportunities for pharmaceutical companies to innovate while addressing pressing health concerns, shaping the future of India's healthcare.

The government of India also acknowledges the importance of drug repurposing in its healthcare initiatives, seeking to foster collaborations and streamline regulatory pathways to accelerate the process, thus reinforcing the viability and importance of these Types in the market landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Drug Repurposing Market Therapeutic Area Insights**

The Therapeutic Area segment of the India Drug Repurposing Market is experiencing noteworthy growth, driven by a combination of factors such as rising healthcare costs, a growing aging population, and an increase in chronic diseases across the country. Within this segment, the approach of repurposing drugs within the Same Therapeutic Area has gained traction as it utilizes existing medications for new therapeutic indications, significantly shortening the development timeline and reducing associated costs. This strategy is attracting attention due to its potential to quickly meet unmet medical needs, enhancing treatment options for patients while maximizing the value of established drugs.

On the other hand, the Different Therapeutic Area aspect showcases the versatility of repurposed drugs as their existing mechanisms can often be effective against various diseases, leading to innovative applications. This adaptability not only facilitates quicker market entry but also allows for the exploration of novel treatment pathways in emerging therapeutic landscapes. The India Drug Repurposing Market segmentation reveals unique opportunities and challenges, reflecting the diverse nature of therapeutic needs and the ongoing shift towards more efficient drug development strategies, making it an area ripe for investment and research.

**Drug Repurposing Market Drug Molecules Insights**

The Drug Molecules segment within the India Drug Repurposing Market plays a crucial role in the evolving pharmaceutical landscape, especially in enhancing existing therapeutic uses of established compounds. Biologics are increasingly significant due to their ability to target specific pathogens and disease pathways, offering opportunities for novel treatments with enhanced efficacy in chronic and complex conditions.

Small Molecules, on the other hand, dominate the market due to their ease of administration and potential for oral delivery, making them accessible in diverse therapeutic areas such as oncology, infectious diseases, and central nervous system disorders.The growth of the India Drug Repurposing Market is fueled by rising healthcare demands, increased R&D investments, and expanding collaborations between public and private sectors aimed at repositioning drugs. 

Furthermore, the Indian government is actively supporting initiatives for drug discovery and development through various policies and incentives, catalyzing opportunities in drug repurposing. However, challenges such as regulatory hurdles and the need for comprehensive clinical data persist, influencing the market dynamics. Overall, the Drug Molecules segment is poised for significant growth, driven by innovation and the ongoing search for effective therapies to meet healthcare challenges in India.

**India Drug Repurposing Market Key Players and Competitive Insights**

The India Drug Repurposing Market is experiencing substantial growth as pharmaceutical companies and research institutions increasingly focus on utilizing existing drugs to target new therapeutic indications. This approach not only accelerates the drug development process but also minimizes costs and risks associated with bringing a completely new drug to market. The competitive landscape is characterized by a mix of established companies and innovative startups, all striving to carve out a niche for themselves by leveraging their unique assets, such as research capabilities, partnerships, and regulatory expertise. 

As more stakeholders enter the market, they are continuously seeking to explore novel applications for existing therapies, capitalizing on regulatory frameworks that support drug repurposing.Emcure Pharmaceuticals has established a strong presence within the India Drug Repurposing Market, focusing on leveraging its extensive portfolio and research capabilities. The company is known for its robust R&D infrastructure, which enables efficient development of repurposed drugs, aligning well with the current market dynamics that favor quicker time-to-market strategies. Emcure's strengths lie in its strong relationships with healthcare providers and regulatory bodies, ensuring streamlined pathways for product approvals. 

Additionally, the company is committed to addressing unmet medical needs, which positions it favorably as it explores potential new uses for its existing therapeutic agents. With a patient-centric approach and continuous investments in innovation, Emcure Pharmaceuticals is well-equipped to navigate the complexities of the drug repurposing landscape in India.Cipla has carved a significant niche in the India Drug Repurposing Market by focusing on strategic collaborations, research excellence, and a diverse product range that includes critical therapeutic areas.

The company offers a variety of generic and branded pharmaceuticals and is known for its commitment to accessible healthcare solutions. Cipla's strengths in the repurposing domain are amplified by its extensive experience in the pharmaceutical industry and a strong network of healthcare professionals that facilitates research and development collaborations. Key products in Cipla’s portfolio are being investigated for new therapeutic indications, reflecting its proactive approach to drug repurposing. 

Additionally, Cipla engages in strategic mergers and acquisitions to augment its capabilities and enhance its market presence. This enables the company to strengthen its R&D initiatives, ultimately enriching its offerings in the drug repurposing space within India.

**Key Companies in the India Drug Repurposing Market Include**

**India Drug Repurposing Market Industry Developments**

Recent developments in the India Drug Repurposing Market have shown a significant shift as key players like Emcure Pharmaceuticals and Dr. Reddy's Laboratories focus on innovative strategies to enhance their drug portfolios. In September 2023, Cipla announced its plans to expand its repurposing efforts to target chronic diseases, which aligns with India's push toward affordable healthcare solutions. Additionally, in August 2023, Biocon successfully completed clinical trials for a repurposed drug intended for diabetes management, contributing to the broader trend of utilizing existing drugs for new therapeutic purposes.

Current affairs also highlight the competitive landscape, with companies such as Sun Pharmaceutical Industries and Aurobindo Pharma investing in Research and Development aimed at repurposing antibiotics and antivirals. Notably, in July 2023, Glenmark Pharmaceuticals revealed its acquisition of a biotech firm, fortifying its capabilities in drug repurposing. The overall market valuation of the Indian Drug Repurposing Market is anticipated to grow significantly, shaping the future of pharmacological treatments within the region as companies leverage existing drug profiles to address unmet medical needs efficiently.

**India Drug Repurposing Market Segmentation Insights**

## Market Drivers

### Regulatory Framework Enhancements

The evolving regulatory framework in India is playing a pivotal role in shaping the drug repurposing market. The Central Drugs Standard Control Organization (CDSCO) has been streamlining approval processes for repurposed drugs, thereby reducing the time required for market entry. This regulatory support is crucial, as it encourages pharmaceutical companies to invest in repurposing initiatives. In recent years, the CDSCO has introduced guidelines that facilitate faster clinical trials for repurposed drugs, which can lead to quicker access for patients. As the regulatory landscape continues to evolve, it is expected that the drug repurposing market will experience accelerated growth, driven by increased confidence among stakeholders in the approval process.

### Cost-Effectiveness of Drug Repurposing

The economic advantages associated with drug repurposing are driving its growth in the Indian market. Developing new drugs can be prohibitively expensive, often exceeding $2 billion and taking over a decade. In contrast, repurposing existing drugs can significantly reduce development costs and timelines. This cost-effectiveness is particularly appealing to Indian pharmaceutical companies, which are increasingly focusing on innovative solutions to enhance their product portfolios. The drug repurposing market is thus positioned to thrive as stakeholders recognize the potential for quicker returns on investment while addressing unmet medical needs. Furthermore, the Indian government has been promoting initiatives to support affordable healthcare, which aligns with the principles of drug repurposing.

### Rising Burden of Non-Communicable Diseases

The increasing prevalence of non-communicable diseases (NCDs) in India is a significant driver for the drug repurposing market. With conditions such as diabetes, cardiovascular diseases, and cancer on the rise, the healthcare system faces immense pressure. The World Health Organization indicates that NCDs account for approximately 60% of all deaths in India. This alarming statistic highlights the urgent need for effective treatment options. Drug repurposing offers a cost-effective and time-efficient approach to address these health challenges, as existing drugs can be quickly evaluated for new therapeutic uses. Consequently, the drug repurposing market is likely to expand as pharmaceutical companies and researchers seek to leverage existing compounds to combat the growing burden of NCDs.

### Collaboration Between Academia and Industry

The collaboration between academic institutions and the pharmaceutical industry is emerging as a vital driver for the drug repurposing market. In India, numerous universities and research organizations are engaging in partnerships with pharmaceutical companies to facilitate the discovery of new drug applications. These collaborations often result in the pooling of resources, expertise, and data, which can accelerate the drug repurposing process. As a result, the drug repurposing market is likely to benefit from innovative research outcomes and the development of new treatment options. Furthermore, such partnerships can enhance the credibility of repurposed drugs, making them more appealing to healthcare providers and patients.

### Growing Investment in Research and Development

Investment in research and development (R&D) within the Indian pharmaceutical sector is a crucial driver for the drug repurposing market. The Indian government has been actively encouraging R&D through various initiatives, including tax incentives and grants. In 2025, the Indian pharmaceutical industry is projected to reach a market size of $65 billion, with a substantial portion allocated to R&D activities. This influx of funding enables researchers to explore new applications for existing drugs, thereby fostering innovation in the drug repurposing market. As more resources are dedicated to R&D, the potential for discovering novel therapeutic uses for established medications increases, ultimately benefiting patients and healthcare providers alike.

## Future Outlook

The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) in India is poised for growth at 15.0% CAGR from 2025 to 2035, driven by innovation, regulatory support, and unmet medical needs.

**New opportunities:**

- Development of AI-driven drug screening platforms
- Partnerships with biotech firms for clinical trials
- Expansion of telehealth services for patient monitoring

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### India Drug Repurposing Market Segment Insights

India Drug Repurposing Market Segment Insights

### Drug Repurposing Market Types Insights

Drug Repurposing Market Types Insights

The India Drug Repurposing Market encompasses various Types that play a crucial role in addressing unmet medical needs and optimizing the existing drug portfolio. As the market grows, the Types such as Disease-centric, Target-centric, and Drug-centric strategies stand out for their unique approaches to improving healthcare outcomes in the country. Disease-centric strategies focus on repositioning existing drugs to tackle various diseases, significantly boosting treatment options for conditions that currently lack effective therapies.

This approach is particularly important in a diverse healthcare landscape like India, where diseases range from infectious to chronic, thus expanding the scope of available treatments for the vast population.

On the other hand, Target-centric strategies emphasize the molecular targets of drugs, allowing for a more personalized treatment approach. By identifying and utilizing existing medications that can impact specific biological pathways, this method can lead to better patient outcomes, especially in complex diseases like cancer and neurological disorders. This is vital for India, where the burden of chronic diseases is on the rise.

Furthermore, the Drug-centric segment focuses on understanding the properties of established drugs that can be applied to new therapeutic areas, meaning that the existing drug candidates can be rapidly adapted for new uses, which is crucial in a country aiming for sustainable healthcare solutions.

### Drug Repurposing Market Therapeutic Area Insights

Drug Repurposing Market Therapeutic Area Insights

The Therapeutic Area segment of the India Drug Repurposing Market is experiencing noteworthy growth, driven by a combination of factors such as rising healthcare costs, a growing aging population, and an increase in chronic diseases across the country. Within this segment, the approach of repurposing drugs within the Same Therapeutic Area has gained traction as it utilizes existing medications for new therapeutic indications, significantly shortening the development timeline and reducing associated costs. This strategy is attracting attention due to its potential to quickly meet unmet medical needs, enhancing treatment options for patients while maximizing the value of established drugs.

On the other hand, the Different Therapeutic Area aspect showcases the versatility of repurposed [drugs](https://www.marketresearchfuture.com/reports/antimalarial-drugs-market-22076) as their existing mechanisms can often be effective against various diseases, leading to innovative applications. This adaptability not only facilitates quicker market entry but also allows for the exploration of novel treatment pathways in emerging therapeutic landscapes. The India Drug Repurposing Market segmentation reveals unique opportunities and challenges, reflecting the diverse nature of therapeutic needs and the ongoing shift towards more efficient drug development strategies, making it an area ripe for investment and research.

### Drug Repurposing Market Drug Molecules Insights

Drug Repurposing Market Drug Molecules Insights

The Drug Molecules segment within the India Drug Repurposing Market plays a crucial role in the evolving pharmaceutical landscape, especially in enhancing existing therapeutic uses of established compounds. Biologics are increasingly significant due to their ability to target specific pathogens and disease pathways, offering opportunities for novel treatments with enhanced efficacy in chronic and complex conditions.

Small Molecules, on the other hand, dominate the market due to their ease of administration and potential for oral delivery, making them accessible in diverse therapeutic areas such as oncology, infectious diseases, and central nervous system disorders.The growth of the India Drug Repurposing Market is fueled by rising healthcare demands, increased R&D investments, and expanding collaborations between public and private sectors aimed at repositioning drugs. 

Furthermore, the Indian government is actively supporting initiatives for drug discovery and development through various policies and incentives, catalyzing opportunities in drug repurposing. However, challenges such as regulatory hurdles and the need for comprehensive clinical data persist, influencing the market dynamics. Overall, the Drug Molecules segment is poised for significant growth, driven by innovation and the ongoing search for effective therapies to meet healthcare challenges in India.

## Competitive Benchmarking

The drug repurposing market in India is characterized by a dynamic competitive landscape, driven by the increasing need for cost-effective therapeutic solutions and the rising prevalence of chronic diseases. Major players such as Pfizer Inc (US), Novartis AG (CH), and Bristol-Myers Squibb Company (US) are actively engaged in innovative strategies to enhance their market presence. Pfizer Inc (US) focuses on leveraging its extensive research capabilities to identify new applications for existing drugs, thereby streamlining the drug development process. In contrast, Novartis AG (CH) emphasizes strategic partnerships with local biotech firms to accelerate the repurposing of drugs, which allows for a more agile response to market demands. Bristol-Myers Squibb Company (US) is also notable for its commitment to digital transformation, utilizing advanced analytics to optimize its drug repurposing initiatives, thus shaping a competitive environment that prioritizes innovation and collaboration.
The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, which are crucial in a moderately fragmented market. This competitive structure allows for a diverse range of players to influence market dynamics, with larger firms often setting the pace for innovation while smaller entities contribute niche solutions. The collective influence of these key players fosters an environment where agility and responsiveness to market needs are paramount.
In October 2025, Pfizer Inc (US) announced a collaboration with a leading Indian research institute to explore the repurposing of its existing oncology portfolio for new therapeutic indications. This strategic move is significant as it not only enhances Pfizer's research capabilities but also aligns with the growing trend of utilizing local expertise to expedite drug development processes. Such collaborations are likely to yield faster results and improve patient access to innovative therapies.
In September 2025, Novartis AG (CH) launched a new initiative aimed at repurposing its cardiovascular drugs for use in treating rare diseases. This initiative underscores Novartis's commitment to addressing unmet medical needs while diversifying its product offerings. By venturing into rare disease markets, Novartis positions itself to capture new revenue streams and enhance its competitive edge in the drug repurposing landscape.
In August 2025, Bristol-Myers Squibb Company (US) unveiled a digital platform designed to facilitate the identification of potential drug repurposing opportunities through machine learning algorithms. This platform represents a significant advancement in the company's operational capabilities, allowing for more efficient data analysis and decision-making processes. The integration of AI into drug repurposing strategies is likely to enhance the speed and accuracy of identifying viable therapeutic options, thereby reinforcing Bristol-Myers Squibb's position in the market.
As of November 2025, current competitive trends in the drug repurposing market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating drug development timelines. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately reshape the market, fostering an environment where companies that prioritize research and development, alongside strategic partnerships, are more likely to thrive.

## Recent News & Developments

Recent developments in the India Drug Repurposing Market have shown a significant shift as key players like Emcure Pharmaceuticals and Dr. Reddy's Laboratories focus on innovative strategies to enhance their drug portfolios. In September 2023, Cipla announced its plans to expand its repurposing efforts to target chronic diseases, which aligns with India's push toward affordable healthcare solutions. Additionally, in August 2023, Biocon successfully completed clinical trials for a repurposed drug intended for diabetes management, contributing to the broader trend of utilizing existing drugs for new therapeutic purposes.

Current affairs also highlight the competitive landscape, with companies such as Sun Pharmaceutical Industries and Aurobindo Pharma investing in Research and Development aimed at repurposing antibiotics and antivirals. Notably, in July 2023, Glenmark Pharmaceuticals revealed its acquisition of a biotech firm, fortifying its capabilities in drug repurposing. The overall market valuation of the Indian Drug Repurposing Market is anticipated to grow significantly, shaping the future of pharmacological treatments within the region as companies leverage existing drug profiles to address unmet medical needs efficiently.

## Report Scope

| MARKET SIZE 2024 | 25.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 28.75(USD Million) |
| MARKET SIZE 2035 | 116.33(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Amgen Inc (US) |
| Segments Covered | Type, Therapeutic Area, Drug Molecules |
| Key Market Opportunities | Emerging technologies enhance efficiency in the drug repurposing market, driving innovation and regulatory compliance. |
| Key Market Dynamics | Growing interest in drug repurposing driven by regulatory support and technological advancements in India. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the India drug repurposing market in 2024?**
A: The market valuation was $25.0 Million in 2024.

**Q: What is the projected market valuation for the India drug repurposing market by 2035?**
A: The projected valuation for 2035 is $116.33 Million.

**Q: What is the expected CAGR for the India drug repurposing market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 15.0%.

**Q: Which companies are considered key players in the India drug repurposing market?**
A: Key players include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc, and Amgen Inc.

**Q: What are the main segments of the India drug repurposing market?**
A: The main segments include Type, Therapeutic Area, and Drug Molecules.

**Q: What was the valuation for the 'Type' segment in 2024?**
A: The 'Type' segment had a valuation of $25.0 Million in 2024, with Drug-centric at $47.33 Million.

**Q: How does the 'Therapeutic Area' segment perform in terms of valuation?**
A: In 2024, the 'Therapeutic Area' segment was valued at $56.33 Million, with Same Therapeutic Area at $70.0 Million.

**Q: What is the valuation of the 'Drug Molecules' segment in 2024?**
A: The 'Drug Molecules' segment was valued at $66.33 Million in 2024, with Small Molecule leading.

**Q: What does the future hold for the Drug-centric segment by 2035?**
A: The Drug-centric segment is expected to grow significantly, potentially reaching higher valuations by 2035.

**Q: How does the market's growth potential compare between different therapeutic areas?**
A: The market shows varied growth potential, with Different Therapeutic Area valued at $46.33 Million in 2024, indicating diverse opportunities.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-drug-repurposing-market-52394*